Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 15
Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents
Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.
Video Player is loading.
Video content above is prompted by the following:
- Briefly comment on recent data surrounding other antibody-drug conjugates (ADCs) in advanced/recurrent endometrial cancer and discuss the evolving role of these agents in the treatment landscape.
- Anti-TROP2 ADCs
- Sacituzumab govitecan – TROPiCS-03
- Datopotamab deruxtecan – TROPION-PanTumor03
- Sacituzumab tirumotecan
- Anti-FR ADCs
- Luveltamab tazevibulin – STRO-002-GM1
- Rinatabart sesutecan
- Please share future perspectives and closing thoughts on the treatment of endometrial cancer.
Related Content:
